Mylan Launches Generic Precedex Sedative as Hospira Sues FDA

Katie Eder, Senior Editor
Published Online: Tuesday, August 19, 2014
Follow Pharmacy_Times:
Mylan, Inc, today announced it has launched dexmedetomidine hydrochloride injection, a therapeutically equivalent version of Precedex, while Hospira, Inc, has filed a lawsuit to challenge the generic approval.
According to Hospira, the FDA has approved abbreviated new-drug applications for generic versions of its proprietary sedative and “appears poised to grant additional generic applications” based on the agency’s decision on Monday concerning potential label carve-outs proposed by Mylan and other pharmaceutical manufacturers that had filed for a generic form of the drug, according to the Wall Street Journal.
Dexmedetomidine hydrochloride, which is dosed as 100 mcg (base)/mL and packaged in 200 mcg (base)/2 ml single-dose vials, is indicated to sedate patients prior to and/or during surgery and other procedures. Mylan has begun shipping the product immediately, while Hospira has filed a lawsuit in the United States District Court for the District of Maryland, challenging the FDA’s decision.
In a press release, Mylan CEO Heather Bresch said the generic product launch is “another of a number of key approvals that had been pending with (the) FDA (that) represents an important addition to Mylan’s injectables portfolio and growing line of products in the anesthesia and pain management category.”
“As we continue to bring a high quality, reliable supply of injectable products to the US market, Mylan looks forward to delivering on its promise of providing quality medicine and service excellence in the increasingly important institutional space,” Bresch added.
The FDA’s approval of Mylan’s dexmedetomidine hydrochloride injection closely follows a key approval of the pharmaceutical manufacturer’s generic version of Genentech’s Xeloda tablets, which are indicated as monotherapy, adjuvant therapy, and combination therapy for certain types of breast, colon, and colorectal cancers. Currently, Mylan has 295 ANDAs pending approval, according to IMS Health.
IMS Health also reported that dexmedetomidine hydrochloride had US sales of approximately $156.2 million for the 12 months ending June 30, 2014, while capecitabine tablets had US sales of approximately $773.8 million in the same period.
Related Articles
Preventing exposures to blood and body fluids is critical to preventing occupationally acquired HIV.
Even short-term treatment with nonsteroidal anti-inflammatory drugs is associated with significant increases in bleeding and cardiovascular event risk in patients receiving antithrombotic therapy after a heart attack.
A patient’s hospital readmission likelihood relies more heavily on community factors than care at discharge, according to a study published in Health Services Research.
The US Centers for Disease Control and Prevention today reported that nearly half a million Clostridium difficile infections occurred in a single year, highlighting a critical need for improved antibiotic use.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times